HOME NEWS EARNINGS RESULTS PICKS STRATEGY BLOG CONTACT SUBSCRIBE LOGIN SUBSCRIBE JOIN FREE
LOADING
Price Investing Group
← Back to Research Watchlist
IBRX
ImmunityBio Inc
Healthcare Biotechnology · California, USA · Reports in usd
Market Cap: $8.25B
Market Cap
$8.25B
Enterprise Val
$8.85B
P/E Ratio
-23.49
P/B Ratio
-16.49
Trailing PEG (1Y)
1.64
As Of
May 5, 2026

Overview & Key Metrics

Reporting period: Dec 31, 2025 · Q4 2025
Book Value-$499.6M
Gross Margin99.00%
Profit Margin99.00%
Return on Equity64.27%
Return on Assets-81.40%
Current Ratio5.10
Debt/Equity-1.68
LT Debt/Equity-1.67
Revenue Per Share0.04

Income Statement

Dec 31, 2025
Revenue$38.3M
Cost of Revenue$382.0K
Gross Profit$37.9M
R&D$63.9M
SG&A$38.7M
Operating Expenses$102.6M
Operating Income-$64.7M
Interest Expense$27.2M
Tax Expense-$135.0K
Net Income-$61.9M
EPS (Basic)$-0.06
EPS (Diluted)$-0.06
EBIT-$34.9M
EBITDA-$29.5M
Consolidated Income-$62.0M
Non-Controlling Interests-$14.0K

Balance Sheet

Dec 31, 2025
Cash & Equivalents$88.3M
Accounts Receivable$42.6M
Inventory$14.4M
Current Assets$314.9M
LT Investments$7.4M
Property, Plant & Equipment$147.3M
Intangibles$14.0M
Non-Current Assets$187.0M
Total Assets$501.9M
Accounts Payable$7.4M
Current Debt$7.5M
Current Liabilities$61.8M
LT Debt$835.2M
Non-Current Liabilities$939.7M
Total Liabilities$1.00B
Total Debt$842.7M
Retained Earnings-$3.73B
Shareholder Equity-$500.5M
Shares Outstanding984,965,179

Cash Flow Statement

Dec 31, 2025
Operating Cash Flow-$70.4M
Investing Cash Flow$43.6M
Financing Cash Flow$54.9M
CapEx-$1.3M
Free Cash Flow-$71.7M
Depreciation & Amort.$5.4M
Stock-Based Comp$8.7M
Acquisitions / Disposals$0.00
Investment Activity$44.8M
Debt Issued/Repaid$1.7M
Equity Issued/Repaid$53.2M
Dividends Paid$0.00
Net Change in Cash$28.1M
Data cached · Meta live · Daily live · Statements live · TTL 24h